Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions: Original Article

Diabetic Medicine

Volumn 27, Issue 6, 2010, Pages 691-695

  Pala, L ^a   Ciani, S ^a   Dicembrini, I ^a   Bardini, G ^a   Cresci, B ^a   Pezzatini, A ^a   Giannini, S ^a   Mannucci, E ^b   Rotella, C M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Diabetes mellitus; Dipeptidyl peptidase IV; Glucagon like peptide 1

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; WAIST CIRCUMFERENCE;

AGED; AREA UNDER CURVE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; FASTING; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MIDDLE AGED; WAIST CIRCUMFERENCE;

EID: 77952704834     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.03010.x     Document Type: Article

References (20)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987 2 : 1300 1304.
2. Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009 297 : 127 136.
3. Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999 44 : 81 86.
4. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E et al. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus. Diabet Med 2000 17 : 713 719.
5. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentration of intact biologically active glucagon-like peptide-1 in type 2 diabetic patients. Diabetes 2001 50 : 609 613.
6. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999 22 : 1137 1143.
7. Green BD, Gault VA, O'Harte FP, Flatt PR. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future anti-diabetic agents. Curr Pharm Des 2004 10 : 3651 3366.
8. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase-IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1-(7-36) amide, peptide histidine methionine, and is responsible for their degradation in human serum. Eur J Biochem 1993 214 : 829 835.
9. Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003 88 : 220 224.
10. Pala L, Mannucci E, Pezzatini A, Ciani S, Sardi J, Raimondi L et al. Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 2003 310 : 28 31. (Pubitemid 37162757)
11. Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, Sposato I et al. Hyperglycaemia increases dipeptidyl peptidase-IV activity in diabetes mellitus. Diabetologia 2005 48 : 1168 1172.
12. Alberti KGMM, Zimmet PZ, for the WHO consultation. Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Med 1998 15 : 539 553.
13. Durinx C, Neels H, Van der Auwera JC, Naelaerts K, Scharpe S, De Meester I. Reference values for plasma dipeptidyl peptidase-IV activity and their association with other laboratory parameters. Clin Chem Lab Med 2001 39 : 155 158.
14. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P et al. INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005 366 : 1640 1649.
15. McArdle N, Hillman D, Beilin L, Watts G. Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med 2007 175 : 190 195.
16. Monami M, Pala L, Bardini G, Francesconi P, Cresci B, Marchionni N et al. Glomerular hyperfiltration and metabolic syndrome: results from the FIrenze-BAgno A Ripoli (FIBAR) Study. Acta Diabetol 2009 46 : 191 196.
17. Augustyns K, Bal G, Thonus G, Belyaev A, Zhang XM, Bollaert W et al. The unique properties of dipeptidyl-peptidase IV (DPP IV/CD 26) and the therapeutic potential of DPP-IV inhibitors. Curr Med Chem 1999 6 : 311 327.
18. Tai M. A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 1994 17 : 152 154.
19. Rask E, Olsson T, Söderberg S, Holst JJ, Tura A, Pacini G et al. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism 2004 53 : 624 631.
20. lc levels, but is not acutely affected by food intake. Eur J Endocrinol 2006 155 : 485.